StockData
QuidelOrtho Corp logo

QuidelOrtho Corp (QDEL) bonds

QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)

Close on Nov 18, 2026Market cap $656.27MP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 27, 2026

Total debt
$2.94B
$424.40M due within a year
Net debt
$2.77B
After $166.40M of cash
Implied interest rate
6.92%
FY2025 interest ÷ average debt
Interest coverage
-5.2×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 28, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in QuidelOrtho's 10-Q for the period ended Jun 28, 2026

QuidelOrtho's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeAvailableDrawn
Credit Agreement$700.00M$426.50M$250.00M
Delayed Draw Term Loan A$100.00M–$100.00M
Term Loan A$1.15B–$1.14B
Term Loan A Facilities––$1.22B
Term Loan B$1.45B–$1.44B

See a number that looks wrong?